Neurocrine Biosciences Highlights Key Outcomes from KINECT-PRO Study
Neurocrine Biosciences Showcases Insights from KINECT-PRO Study
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has recently released promising findings from the KINECT-PRO™ study, which evaluates the impacts of INGREZZA® (valbenazine) capsules on patients dealing with tardive dyskinesia (TD). This Phase 4 study has demonstrated significant improvements in patients’ functionality and quality of life associated with their involuntary movements.
A Groundbreaking Study for Tardive Dyskinesia
The KINECT-PRO study marks an important milestone as it is the first to comprehensively assess the patient-reported outcomes related to the administration of a vesicular monoamine transporter 2 (VMAT2) inhibitor for TD. Researchers employed validated assessment scales to capture the patient experience and overall effect on quality of life. The data sets provide an in-depth look into how INGREZZA impacts everyday life for those affected by TD.
Understanding the Study Participants
In total, fifty-nine individuals participated in the KINECT-PRO study, all of whom received a daily dosage of INGREZZA for a duration of 24 weeks. Participants included patients with mild to severe forms of TD, regardless of their underlying psychiatric conditions, ensuring a diverse representation of those affected by this challenging disorder.
Evaluating the Impact on Daily Life
The study's primary goal was to analyze how INGREZZA alters the patient experience in terms of physical and socio-emotional wellness. Assessments were conducted at multiple intervals—Weeks 4, 8, 16, and 24—to track the evolution of their symptoms using various validated tools, including the Tardive Dyskinesia Impact Scale (TDIS) and the Sheehan Disability Scale (SDS).
Significant Results from the Study
Findings indicated consistent and meaningful improvements across all measures. Patients witnessed these enhancements as early as the first few weeks of treatment, highlighting the effectiveness of INGREZZA. Additionally, AIMS scores revealed a sustained decrease in involuntary movements, with safety data remaining consistent with what is already known about the drug’s profile.
About INGREZZA and Its Mechanism
INGREZZA is a selective VMAT2 inhibitor, approved by the U.S. Food and Drug Administration, intended for adults grappling with tardive dyskinesia and chorea associated with Huntington's disease. This unique medication works by inhibiting dopamine release, ultimately leading to fewer involuntary movements for users.
Patient Needs Taken into Account
One remarkable aspect of INGREZZA is its flexible dosing options, allowing healthcare professionals to tailor treatment strategies based on individual patient needs. This adaptability is critical, especially for those who face challenges such as dysphagia, for whom INGREZZA SPRINKLE offers an innovative alternative.
Enhancing Awareness of Tardive Dyskinesia
Tardive dyskinesia, characterized by uncontrollable movements, can significantly disrupt a patient’s quality of life. Understanding both the medical and emotional burdens of this condition is crucial. Neurocrine Biosciences aims to raise awareness about TD through such vital research initiatives, encapsulating the real-life implications of this disorder.
Future Directions and Research
The company’s commitment to answering the challenges posed by neurological and neuropsychiatric disorders continues with the KINECT-PRO findings. By sharing these insights at future scientific conferences, Neurocrine hopes to further dialogue around effective treatments and interventions.
Frequently Asked Questions
What is the KINECT-PRO study about?
The KINECT-PRO study investigates the effectiveness of INGREZZA in improving the quality of life and functionality for patients experiencing tardive dyskinesia.
What does INGREZZA do?
INGREZZA is a selective VMAT2 inhibitor that helps decrease involuntary movements associated with tardive dyskinesia.
What were the key findings of the study?
Participants exhibited significant improvements across various measures of functionality and quality of life after treatment with INGREZZA, starting as early as four weeks.
How long did the study last?
The KINECT-PRO study lasted a total of 24 weeks, with assessments made at multiple intervals throughout the duration.
Who can benefit from INGREZZA?
Adolescents and adults experiencing tardive dyskinesia or chorea associated with Huntington's disease can potentially benefit from INGREZZA, pending physician evaluation.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.